Nektar Therapeutics shed billions in market value after a disappointing clinical trial update for investors. Shares of Bristol-Myers Squibb, Nektar’s development partner, also slid.
from WSJ.com: Markets https://ift.tt/2JiPI9D
via https://ifttt.com/ IFTTT
No comments:
Post a Comment